本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-052 青岛蔚蓝生物股份有限公司 2025年第一次临时股东会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 102 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 166,723,780 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 65.8912 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式召开。 公司董事长兼总经理陈刚因出差在外无法出席本次股东会，经过半数董事推选， (一) 股东会召开的时间：2025 年 11 月 13 日 (二) 股东会召开的地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会议室 (三) 出席会议的普通股股东和恢 ...

北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 2025 年第一次临时股东会的 法律意见书 中国·北京 地址：朝阳区建外大街甲 14 号广播大厦 5 层、9 层、10 层、13 层、17 层 邮编：100022 电话：（010）65219696 传真：（010）88381869 二〇二五年十一月 北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 2025 年第一次临时股东会的法律意见书 致：青岛蔚蓝生物股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受青岛蔚蓝生物股份有限 公司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第一次临时股 东会，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治 理准则》《公司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、 召开程序、出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜 出具本法律意见书。 对本法律意见，本所律师声明如下： 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行 ...

Group 1: Report General Information - The report is about a research on Weilan Biology in the agricultural, livestock, and fishery industry on November 5, 2025 [1][2][17] Group 2: Research Participants - The research was participated by investors through online questions [2] - The company's reception staff included the chairman and general manager Chen Gang, director and financial controller Qiao Piyuan, board secretary Jiang Yong, and independent directors Lin Yingtin and Wang Jing [17] Group 3: Company's Development Strategy - The company focuses on the biological industry, aiming to become a world - class high - tech biological enterprise. It will form a new development pattern of "one body with two wings", building an industrial biological platform company driven by technological innovation and globalization [24] - The company adheres to technological innovation as the core strategy and has launched the "ecological innovation" strategy, building an open - innovation ecosystem [24] - The company takes global layout as an important strategy, aiming to increase the proportion of overseas revenue and expand into key regions like Southeast Asia and Africa [25][26] Group 4: Q3 Financial Performance - In Q3 2025, the company's operating income was 363.5997 million yuan, a year - on - year increase of 8.09% due to product sales structure adjustment; the net profit attributable to the parent was 35.0628 million yuan, a year - on - year increase of 205.02% due to the recognition of income from cooperation partners [26] Group 5: Technical Advantages in Animal Health - The company builds an "industry + service" comprehensive empowerment platform in the animal health field, providing systematic solutions [27] - The VLAND - PCP customized enzyme program has a database covering over a hundred feed ingredients, improving feed conversion efficiency and livestock growth performance [27] Group 6: R & D Investment and Progress - In the first three quarters of 2025, the company's R & D investment was 100.2386 million yuan, accounting for 9.87% of operating income, a year - on - year increase of 23.29% [28] - The company has 6 technology centers and 2 key laboratories, adopting a "dual - leadership" management model and an IPD system for R & D management [29][30] - The company cooperates with over 20 universities and research institutes and 60 large - and medium - sized production enterprises for R & D [30] Group 7: Microbial Technology in Environmental Protection - The company established the Weilan Saide Environmental Microbial Laboratory, applying microbial technology to environmental protection, but the business revenue accounts for a relatively small proportion [31]

青岛蔚蓝生物股份有限公司 2025 年第一次临时股东会 会议材料 二〇二五年十一月十三日 | 2025 年第一次临时股东会会议议程 1 | | --- | | 2025 年第一次临时股东会会议须知 2 | | 2025 年第一次临时股东会会议议案 3 | | 议案一： 3 | | 关于取消监事会并修订《公司章程》的议案 3 | | 议案二： 49 | | 关于修订、制定公司部分治理制度的议案 49 | 青岛蔚蓝生物股份有限公司 2025 年第一次临时股东会会议议程 一、会议召开的基本情况 （一）会议类型和届次：2025 年第一次临时股东会 （二）会议召开时间、地点： 会议时间：2025 年 11 月 13 日 14 点 30 分 会议地点：青岛市崂山区九水东路 596-1 号蔚蓝生物创新园 B 座多媒体会议 （三）会议出席人员 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 二、会议议程 （一）报告会议出席情况，宣布会议开始； （二）本次股东会各项议案宣读并审议； （三）股东或股东代表发言及公司董事、监事、高级管理人员回答提问； （四）记名投票表决（由股东、监事及律师组 ...

Group 1 - The core point of the article highlights a significant increase in the stock price of Hualan Vaccine by 18%, indicating positive market sentiment towards the company [1] - Other companies in the vaccine and biopharmaceutical sector, including Watson Bio, Teva Pharmaceutical, Hualan Biological, Weilan Bio, Hendi Pharmaceutical, Wantai Bio, and Baike Bio, also experienced stock price increases, suggesting a broader trend in the industry [1]

Core Insights - The company, Weilan Bio, was established on February 23, 2005, and went public on January 16, 2019, on the Shanghai Stock Exchange, with its registered and office locations in Shandong Province. It is a representative enterprise in the enzyme preparation and probiotic fields in China, with notable advantages in technology research and development [1] Financial Performance - For Q3 2025, Weilan Bio reported a revenue of 1.016 billion yuan, ranking 14th out of 24 in the industry. The top two competitors, Meihua Biological and Xinhengcheng, reported revenues of 18.215 billion yuan and 16.642 billion yuan, respectively, while the industry average was 357.1 million yuan [2] - The net profit for the same period was 82.93 million yuan, placing the company 15th in the industry. The leading competitors reported net profits of 5.354 billion yuan and 3.025 billion yuan, with the industry average at 539 million yuan [2] Financial Ratios - As of Q3 2025, Weilan Bio's debt-to-asset ratio was 37.49%, down from 38.62% year-on-year, which is higher than the industry average of 28.46% [3] - The company's gross profit margin for Q3 2025 was 44.45%, slightly up from 44.18% year-on-year, and also above the industry average of 28.77% [3] Management and Shareholder Information - The chairman and general manager, Chen Gang, received a salary of 1.97 million yuan in 2024, an increase of 499,300 yuan from 2023 [4] - As of September 30, 2025, the number of A-share shareholders decreased by 22.70% to 17,000, while the average number of circulating A-shares held per account increased by 29.36% to 14,900 [5] Strategic Outlook - According to Minsheng Securities, Weilan Bio's revenue and net profit showed fluctuations in the first half of 2025, with Q2 performance improving. The company is focusing on innovation strategies, with significant results in food probiotics and animal health products. The capacity layout is nearing completion, enhancing multi-business synergy [5] - Guoxin Securities noted that the company expects steady revenue growth in 2024 and Q1 2025, with the capacity layout nearly finished. The R&D-driven gross margin for enzyme products is expected to continue rising, benefiting from market expansion due to alternatives to feed antibiotics [5]

Market Overview - The chemical products sector increased by 1.38% on October 29, with JinHua New Materials leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Top Performers - JinHua New Materials (Code: 920015) closed at 62.92, up 30.00% with a trading volume of 135,600 shares and a turnover of 746 million [1] - WeiLan Bio (Code: 603739) closed at 15.51, up 10.00% with a trading volume of 96,900 shares and a turnover of 148 million [1] - YiNuoWei (Code: 920261) closed at 16.34, up 7.08% with a trading volume of 48,000 shares and a turnover of 75.93 million [1] Underperformers - XianFeng New Materials (Code: 300163) closed at 4.61, down 7.62% with a trading volume of 1,672,400 shares and a turnover of 787 million [2] - JinJi Co., Ltd. (Code: 300798) closed at 7.63, down 5.92% with a trading volume of 230,600 shares and a turnover of 178 million [2] - KaiLi New Materials (Code: 6888889) closed at 41.10, down 5.30% with a trading volume of 40,900 shares and a turnover of 170 million [2] Capital Flow - The chemical products sector experienced a net outflow of 84.36 million from institutional investors, while retail investors saw a net inflow of 87.49 million [2][3] - Major stocks like KaiMeiTeQi (Code: 002549) had a net inflow of 200 million from institutional investors, while DeMeiHuaGong (Code: 002054) saw a net outflow of 155 million [3]

Group 1 - The agricultural, animal husbandry, and fishery sector experienced a volatile upward trend on October 29, with the highest "pig content" agricultural ETF (159275) reaching a peak intraday increase of 0.81% and closing up 0.51% [1] - Key stocks in the sector included Blue Biological, which hit the daily limit, Meino Biological with over 8% increase, Luoniushan up 6%, and Shennong Seed Industry rising over 5% [1] - The current valuation of the agricultural, animal husbandry, and fishery sector is relatively low, indicating a good time for allocation, with the market's highest "pig content" ETF (159275) having a price-to-book ratio of 2.57, at the 30.08% percentile of the last decade [3] Group 2 - The "anti-involution" measures in the pig industry have been intensified since May, with multiple meetings held by the Ministry of Agriculture, the National Development and Reform Commission, and industry associations to control production capacity and reduce weights [1][4] - It is expected that the pig price will enter a new upward trend in the second half of next year due to accelerated capacity reduction in the fourth quarter [1][4] - The agricultural ETF (159275) tracks the CSI Agricultural, Animal Husbandry, and Fishery Index, with a significant portion (40.25%) of its holdings in the pig farming industry, higher than similar ETFs [8]

Group 1 - The adjustment of the value-added tax rate will not affect the company's performance in 2024 and prior years, but it is expected to have an indirect impact on the company's total profit starting in 2025 [1] - The company has implemented measures to mitigate the impact of the tax rate adjustment, including optimizing product pricing and structure, strengthening tax management and cost control, aligning with market demand, and enhancing customer loyalty [1] - The specific financial impact of the tax rate adjustment will be determined by the audit report issued by the accounting firm [1] Group 2 - The company will hold its first extraordinary general meeting of shareholders in 2025 on November 13 at 14:30, located at the Vland Innovation Park in Qingdao [4][5] - Voting for the meeting will be conducted through a combination of on-site and online methods, with specific time slots for online voting [5][6] - Shareholders must register to attend the meeting, with detailed registration methods provided for different types of shareholders [11][12][13]

Core Points - The company has announced the cancellation of its supervisory board and the revision of its articles of association, with the responsibilities of the supervisory board being transferred to the audit committee of the board of directors [30][31]. - The company held its 21st meeting of the fifth board of directors on October 28, 2025, where several important resolutions were passed, including the approval of the third quarter report for 2025 [9][10]. - The company plans to hold its first extraordinary general meeting of 2025 on November 13, 2025, to discuss the cancellation of the supervisory board and other governance matters [27]. Financial Data - The third quarter financial report for 2025 has been prepared but is not audited [3][4]. - The report includes significant non-recurring gains and losses, although specific amounts are not detailed in the provided documents [4]. Governance Changes - The company will no longer have a supervisory board, and its functions will be assumed by the audit committee, with necessary amendments made to the articles of association [31]. - Various governance documents and rules are being revised or established to enhance the company's operational standards, including rules for shareholder meetings and board meetings [16][20][21]. Shareholder Information - The company has confirmed that the resolutions passed during the board meeting received unanimous support, with all five directors voting in favor [12][15][28].